Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCagen · Entity 5774 | Chief Medical Officer | March 31, 2017 | April 04, 2017 |
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Medical Officer | March 01, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date March 31, 2017 · Filed April 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option, Right to buySEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2027-03-31 | Direct | 232,500 |
Reported balance
After 2017-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-31 · Grant · Acquired 232,500 · Balance 232,500 F1: Options vest one-third on the one year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest one-third on the one year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date.
Acrivon Therapeutics, Inc.
Report date March 01, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2035-02-28 | Direct | 78,078 |
Reported balance
After 2025-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-01 · Grant · Acquired 78,078 · Balance 78,078 F1: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2025 Filed Mar 4, 2025 17:13 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 78,078 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000831 · form4.xml · derivative · entry 1 Cuillerot Jean-Marie · CIK 0001696108 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,078 Underlying: Common Stock · 78,078 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 16:45 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 99,300 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0000905148-24-000183 · form4.xml · derivative · entry 1 Cuillerot Jean-Marie · CIK 0001696108 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,300 Underlying: Common Stock · 99,300 shares Expires 2034-01-10 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 1, 2025, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:27 UTC | AGENUS INC agen · Entity 5774 | GrantStock Option, Right to buy · Derivative | 232,500 | $3.77 Strike: $3.77 | $876,525.00 |
DisclosureSEC source: 0001288123-17-000009 · primary_doc.xml · derivative · entry 1 Cuillerot Jean-Marie · CIK 0001696108 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,500 Underlying: Common Stock · 232,500 shares Expires 2027-03-31 F1 · derivative.exercise_date: Options vest one-third on the one year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:09 UTC | AGENUS INC agen · Entity 5774 | GrantStock Option, Right to Buy · Derivative | 100,000 | $3.72 Strike: $3.72 | $372,000.00 |
DisclosureSEC source: 0001288123-17-000006 · primary_doc.xml · derivative · entry 1 Cuillerot Jean-Marie · CIK 0001696108 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Plan and vests in three equal annual installments beginning on the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.